- The Washington Times - Sunday, February 19, 2006


A fter 61 years of pumping blood, Marie Carty’s heart was failing her. Months earlier, she had given up her two-mile walk on the boardwalk of her New Jersey hometown along the Atlantic Ocean. She could barely make it from the parking lot to the view of the water.

Although Mrs. Carty knew she needed a new heart, she was afraid hers wouldn’t last during the long wait for a transplant.

Desperate for an alternative, Mrs. Carty found the Israeli-Thai company TheraVitae, which has begun performing an experimental procedure that multiplies stem cells taken from a patient’s own blood and injects them into the ailing heart in hopes of strengthening it.

The procedure performed by TheraVitae and a handful of other companies could offer new hope to hundreds of thousands of heart patients around the world.

The U.S. Food and Drug Administration has not approved the procedure for use in the United States, and though doctors hope it can be a substitute for heart transplants, the permanence of the repairs has yet to be ascertained.

“It’s too early to know the long-term effects of these types of procedures,” said Dr. Vincent Pompili, director of interventional cardiology at Case Western Reserve University in Cleveland.

Hopes raised

Several teams of doctors around the world — including at least three in the United States — say they are seeing promising results in similar trials using stem cells extracted from bone marrow.

Proponents of TheraVitae’s procedure say it is simpler and less painful to get stem cells from blood than extracting them from bone marrow.

The procedure involves no risk of rejection because the cells are the patient’s own, supporters say. It also does not use embryonic stem cells, an idea that has raised moral objections because they require the destruction of human embryos.

Many scientists think stem cells could herald a new era of regenerative medicine, leading to cures for conditions ranging from diabetes to Parkinson’s disease.

61-year-old has energy

After a two-week trip in the fall to Thailand for the operation, Mrs. Carty is once again walking two miles on the boardwalk in Little Silver. Her strengthened heart led doctors to remove her from the transplant list.

“The change is like night and day,” said Mrs. Carty, who works in property management. “I feel myself again, more energy, more stamina.”

Mrs. Carty is one of 70 people who have undergone TheraVitae’s procedure, said Valentin Fulga, chief executive of the company. All have shown improvement, he said.

The list also includes Hawaiian crooner Don Ho, who underwent the operation in early December in Thailand.

“I’m feeling much better ,and I’m so happy I came up here to do it,” the 75-year-old entertainer said after the procedure.

Mr. Fulga said patients who get the procedure are generally heart transplant candidates or people who have undergone bypass surgery without positive results.

More research needed

“We believe that these cells have the capacity of turning into blood vessels,” he said. “The treatment seems to be not only very safe, with no side effects, but also effective because they improve.”

Mr. Fulga agrees, however, that with the procedure in trials for less than two years, there is still a lot to learn. For instance, he said, it’s possible that over time the cells that repair the heart could lose their effectiveness.

Mr. Fulga also said it is not known exactly how the cells inserted into the heart improve the patient’s condition. But it is thought they help reconstruct blood capillaries and vessels and the heart muscle itself, capitalizing on the body’s natural healing processes, he said.

The treatment involves withdrawing blood from a patient and spinning it in a centrifuge to separate out — by weight and size — the cells needed for the procedure. This batch of cells, called VesCell by the company, is composed of stem cells and other cells beneficial to the process.

Eye on the future

Mr. Fulga and Thai entrepreneur Robert Clark founded TheraVitae in 2003. Patients travel to Thailand for the extraction of the blood and wait less than a week while it is sent to Israel. There the stem cells are harvested and expanded, then shipped back to Thailand, where the operation to insert them is performed.

The total cost is about $35,000, including air fare and lodging, Mr. Fulga said.

He said he expects to meet with FDA officials within six months and hopes to get approval to begin conducting trials in the United States.

Dr. Mark Zucker, director of heart failure and transplantation at Newark Beth Israel Medical Center in New Jersey, said therapy using adult stem cells is the way of the future. His center is considering working with TheraVitae.

Dr. Zucker said that if doctors at TheraVitae have discovered how to make stem cells heal heart tissue, this could be a real solution for tens of thousands of Americans, because only 2,300 hearts become available for transplant in the United States each year.

“I believe TheraVitae is on the right track,” Dr. Zucker said. “I think if the company has identified an efficient way to procure cells and expand them, the company’s impact will be revolutionary.”

The company presented its findings at a conference of the American Heart Association in Dallas in November. It has been chosen, with 35 other companies, as a technology pioneer for 2006 by the World Economic Forum.

Dr. Pompili said he is working through a company called Arteriocyte Inc. on a similar procedure, harvesting stem cells from bone marrow. He said his company and two other teams of doctors in the United States are conducting FDA trials using stem-cell therapy to heal heart tissue.

Copyright © 2019 The Washington Times, LLC. Click here for reprint permission.

The Washington Times Comment Policy

The Washington Times welcomes your comments on Spot.im, our third-party provider. Please read our Comment Policy before commenting.


Click to Read More and View Comments

Click to Hide